Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
作者信息
Loomba Rohit, Ratziu Vlad, Harrison Stephen A
机构信息
NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California.
Sorbonne Université, Institute of Cardiometabolism and Nutrition, Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Gastroenterology. 2022 Mar;162(3):680-688. doi: 10.1053/j.gastro.2021.10.051. Epub 2021 Nov 23.
Abstract
摘要
相似文献
1
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
Gastroenterology. 2022 Mar;162(3):680-688. doi: 10.1053/j.gastro.2021.10.051. Epub 2021 Nov 23.
2
Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.
Hepatology. 2021 May;73(5):2023-2027. doi: 10.1002/hep.31687.
3
Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift.
J Clin Pharmacol. 2021 Jun;61(6):740-743. doi: 10.1002/jcph.1862. Epub 2021 Apr 20.
4
Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.
Clin Pharmacol Ther. 2021 Feb;109(2):292-294. doi: 10.1002/cpt.1978. Epub 2020 Aug 2.
5
Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development.
J Clin Pharmacol. 2021 Jun;61(6):736-739. doi: 10.1002/jcph.1806. Epub 2021 Jan 12.
6
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.
Expert Opin Drug Discov. 2021 Feb;16(2):125-134. doi: 10.1080/17460441.2020.1811674. Epub 2020 Oct 22.
7
Developing Pharmacologic Treatments for Eosinophilic Esophagitis: Draft Guidance from the United States Food and Drug Administration.
Gastroenterology. 2019 Aug;157(2):275-277. doi: 10.1053/j.gastro.2019.04.020. Epub 2019 Apr 22.
8
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048. Epub 2019 Sep 12.
9
2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Curr Drug Metab. 2020;21(6):403-426. doi: 10.2174/1389200221666200620210522.
10
Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study.
Br J Pharmacol. 2018 Nov;175(22):4229-4238. doi: 10.1111/bph.14485. Epub 2018 Oct 1.
引用本文的文献
1
Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index.
Dig Dis Sci. 2025 Sep 3. doi: 10.1007/s10620-025-09361-9.
2
A systematic review and meta-analysis of efruxifermin's efficacy in improving liver fibrosis in patients with NASH/MASH.
Front Pharmacol. 2025 May 30;16:1594091. doi: 10.3389/fphar.2025.1594091. eCollection 2025.
3
Role of artificial intelligence in advancing immunology.
Immunol Res. 2025 Apr 24;73(1):76. doi: 10.1007/s12026-025-09632-7.
4
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.
Nat Rev Gastroenterol Hepatol. 2025 May;22(5):314-328. doi: 10.1038/s41575-025-01045-z. Epub 2025 Feb 17.
5
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.
Nat Med. 2025 Mar;31(3):988-995. doi: 10.1038/s41591-024-03480-y. Epub 2025 Jan 27.
6
Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis.
Int J Mol Sci. 2024 Nov 28;25(23):12782. doi: 10.3390/ijms252312782.
7
Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease.
World J Gastroenterol. 2024 Dec 14;30(46):4964-4968. doi: 10.3748/wjg.v30.i46.4964.
8
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).
Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28.
9
Efficacy and safety of electroacupuncture for metabolic dysfunction-associated fatty liver disease: a study protocol for a multicentre, randomised, sham acupuncture-controlled, patient-blinded clinical trial.
BMJ Open. 2024 Nov 14;14(11):e084768. doi: 10.1136/bmjopen-2024-084768.
10
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists.
Hepatol Commun. 2024 Oct 10;8(11). doi: 10.1097/HC9.0000000000000561. eCollection 2024 Nov 1.
本文引用的文献
1
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7.
2
Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
J Hepatol. 2021 Jul;75 Suppl 1:S178-S190. doi: 10.1016/j.jhep.2021.01.007.
3
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
Gut. 2022 May;71(5):983-990. doi: 10.1136/gutjnl-2021-324264. Epub 2021 Apr 21.
4
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
J Hepatol. 2021 Aug;75(2):284-291. doi: 10.1016/j.jhep.2021.02.034. Epub 2021 Mar 18.
5
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Gastroenterology. 2021 Apr;160(5):1608-1619.e13. doi: 10.1053/j.gastro.2020.12.003. Epub 2020 Dec 8.
6
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
J Hepatol. 2020 Dec;73(6):1322-1332. doi: 10.1016/j.jhep.2020.06.025. Epub 2020 Jun 28.
7
Advances in non-invasive assessment of hepatic fibrosis.
Gut. 2020 Jul;69(7):1343-1352. doi: 10.1136/gutjnl-2018-317593. Epub 2020 Feb 17.
8
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.
Hepatology. 2020 Nov;72(5):1605-1616. doi: 10.1002/hep.31173. Epub 2020 Oct 27.
9
Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients.
Can J Gastroenterol Hepatol. 2019 May 2;2019:5862985. doi: 10.1155/2019/5862985. eCollection 2019.
10
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
J Gastroenterol. 2019 Jan;54(1):87-95. doi: 10.1007/s00535-018-1503-x. Epub 2018 Sep 10.
Zotero 插件